

NEXT SCIENCE®

Oraderm Pharmaceuticals appointed as BlastX™ distributor for Australia and New Zealand

Sydney, Australia, Thursday, 19 May 2022: Next Science Limited (ASX:NXS) (**Next Science**) is pleased to announce that it has signed a multi-year distribution agreement for Australia and New Zealand with Oraderm Pharmaceuticals (**Oraderm**), a medical sales joint venture between Douglas Pharmaceuticals (New Zealand's largest privately owned pharmaceutical company) and Arrotex Pharmaceuticals (Australia's largest privately owned pharmaceutical company), for the sale of Next Science's antimicrobial wound gel, BlastX™.

The new distribution agreement grants Oraderm exclusive rights across Australia and New Zealand for the sale and marketing of a dual Next Science / Oraderm labelled version of BlastX™. Revenues arising from the agreement are based on an agreed unit price and a minimum quantity per order. Next Science expects the revenues received from sales of BlastX™ to Oraderm to become material.

The agreement term is 5 years and automatically extends for an additional period of 3 years subject to each party's termination rights.

BlastX™ is an antimicrobial wound gel based on Next Science's patented, non-toxic, biofilm-disrupting Xbio™ technology. BlastX™ deconstructs the bacterial biofilm, the gel envelops and eliminates the bacteria and then defends from recolonisation while maintaining a moist wound environment conducive to healing. The product is ideal for the treatment of non-healing wounds such as foot and leg ulcers and bed sores as well as preventing infections in acute wounds from trauma and surgical incision sites. BlastX™ can be used in hospital, pre-hospital, aged care and other clinical environments as well as in home care.

BlastX™ was cleared by the Australian Therapeutic Goods Administration in May 2021 allowing sales in Australia and New Zealand. The product has also received FDA 510(k) clearance and CE marking (allowing sales in the US, the European Union and the UK) and is approved for sale in Canada.

Oraderm's initial focus in Australia will be hospitals, nursing homes, dermatologists and over-the-counter pharmacy sales using Oraderm's own sales force. In New Zealand, Oraderm will focus on wound care in hospitals and other clinical settings accommodating varied distribution solutions through Douglas Pharmaceuticals' sales team.

Next Science is scheduled to deliver training to the Oraderm and Douglas Pharmaceuticals' sales force in late June with commercial sales in Australia and New Zealand expected to commence during H2 2022.

Chronic wounds continue to be a major health issue for patients across the global community. They are often very difficult to treat, increase pain and suffering, cause a decline in quality of life, increase mortality and add considerable costs to healthcare systems and individuals. It is estimated that more than 400,000 people¹ in Australia suffer from a chronic wound at any time.

¹ <https://news.curtin.edu.au/stories/advancing-treatment-chronic-wounds-essential-australians/#:~:text=Advancing%20the%20treatment%20of%20chronic%20wounds%20is%20essential%20for%20all%20Australians,-News%20story&text=The%20national%20wound%20burden%20in,than%20%242.85%20billion%20annually1>

NXS Managing Director Judith Mitchell commented on the new distribution agreement: “We are delighted to expand our commercial footprint for BlastX in Australia and New Zealand through Oraderm. Oraderm is a well-known brand within the healthcare industry with a track record of success in bringing new products to market. This partnership enhances our ability to offer our proven wound care product to healthcare professionals and patients in Australia and New Zealand as we continue to pursue our mission to heal patients and save lives worldwide by reducing the impacts of biofilms on human health.”

Approved and authorised by Judith Mitchell, Managing Director, Next Science.

Further information:

Judith Mitchell

Managing Director, Next Science Limited

Phone: +61 2 9375 7989

Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory

Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio™ technology. Website: www.nextscience.com.